Company Profile
Updated: 17-SEP-09Oncothyreon Inc.
Public Company, Headquarters Location
2601 4th Ave., Ste. 500, Seattle, WA 98121-3222, United States
(206)801-2100, (206)801-2101 fax, http:///www.oncothyreon.com
Primary SIC: Biological Products Except Diagnostic, Primary NAICS: Biological Product (except Diagnostic) Manufacturing
Description: Manufacturing: Biotechnology and pharmaceutical developing for cancer synthetic vaccines. Services: Commercial physical and biological research and development.
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Oncothyreon shares rise on new late-stage study
AP Online; 12/10/2009; 564 words; Shares of Oncothyreon Inc. rose Thursday after the company...the last 52 weeks. Seattle-based Oncothyreon said the study is expected to enroll...Market Outperform" rating for Oncothyreon with an $8 price target.
FORM 8-K: ONCOTHYREON ANNOUNCES DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS, ELECTION OF DIRECTORS
US Fed News Service, Including US State News; 12/8/2009; 482 words; WASHINGTON, Dec. 7 -- ONCOTHYREON INC., Seattle, files Form 8-K (current report...name of registrant as specified in its charter is ONCOTHYREON INC. State of Incorporation: Delaware Departure of Directors...
ONCOTHYREON REPORTS ACQUISITION BY DIRECTOR HENNEY (Washington)
US Fed News Service, Including US State News; 12/8/2009; 292 words; WASHINGTON, Dec. 8 -- Oncothyreon Inc. (ONTY), Seattle, has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest...
ONCOTHYREON REPORTS ACQUISITION BY DIRECTOR JACKSON (Washington)
US Fed News Service, Including US State News; 12/8/2009; 292 words; WASHINGTON, Dec. 8 -- Oncothyreon Inc. (ONTY), Seattle, has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest...
ONCOTHYREON REPORTS ACQUISITION BY DIRECTOR STOUGHTON (Washington)
US Fed News Service, Including US State News; 12/8/2009; 293 words; WASHINGTON, Dec. 8 -- Oncothyreon Inc. (ONTY), Seattle, has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest...
Recent News Articles
- New Cancer Immunotherapy Index Posts 23% Gains Lead by Mentor Capital, Inc. and Oncothyreon.
Business Wire - August 28, 2009 - PickThatMove.com June 22, 2009, We have picks EnerDel, a subsidiary of Ener1, Inc. (Nasdaq: HEV); Targeted Genetics Corporation (NASDAQ: TGEN); Silicon Image, Inc. (NASDAQ:SIMG) and Oncothyreon Inc. (Nasdaq: ONTY).
M2 Presswire - June 22, 2009 - The Microcap Underground on Stocks to Watch: Oncothyreon Inc, Forest Labs, and Johnson & Johnson.
PR Newswire - June 22, 2009 - Oncothyreon, Inc.-Financial Company Report.
M2 Presswire - February 18, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning